Skip to content

Annexon ANNX Total debt

Total debt at other companies

Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$1.36M-2.3%
Vor Biopharma logo
Vor BiopharmaVOR
$2.94M-90.5%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$2.38M+29.5%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$83.16M-17.1%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$13.61K-99.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+233%
Enterprise value$718.59M+274%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $25.43M.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's total debt?
Annexon (ANNX) reported total debt of $25.43M in Q1 2026.
How has Annexon's total debt changed year-over-year?
Annexon's total debt decreased by 10.2% year-over-year, from $28.31M to $25.43M.
What is the long-term trend for Annexon's total debt?
Over 4 years (2021 to 2025), Annexon's total debt has grown at a -6.7% compound annual growth rate (CAGR), from $34.59M to $26.2M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.